Guardant Health (GH) Net Equity Issued and Repurchased (2018 - 2023)

Guardant Health (GH) posted Net Equity Issued and Repurchased of $90.6 million for Q4 2023, down 64.33% sequentially from $254.0 million in Q4 2018.

Guardant Health (GH) Net Equity Issued and Repurchased (2018 - 2023) Analysis & Trends

Guardant Health has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $90.6 million in Q4 2023.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $90.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $90.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $257.1 million, changed N/A from the prior year.
Net Equity Issued and Repurchased slipped to $90.6 million in Q4 2023 per GH's latest filing, from $254.0 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $90.6 million in Q4 2023 and troughed at $90.6 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Thermo Fisher Scientific	213.40 Bn	209.33 Bn	8.34 Bn	-
2	Danaher	139.94 Bn	135.59 Bn	3.61 Bn	-
3	Idexx Laboratories	46.03 Bn	45.83 Bn	779.09 Mn	-
4	Agilent Technologies	39.69 Bn	37.88 Bn	990.00 Mn	-
5	Iqvia Holdings	39.32 Bn	37.24 Bn	1.44 Bn	-
6	Natera	38.47 Bn	37.37 Bn	696.04 Mn	-
7	Illumina	29.98 Bn	28.82 Bn	770.00 Mn	-
8	Mettler Toledo International	28.57 Bn	28.52 Bn	650.22 Mn	-
9	Quest Diagnostics	26.21 Bn	25.58 Bn	1.03 Bn	-
10	Guardant Health	21.55 Bn	20.49 Bn	219.03 Mn	-

Download Data